Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN
- PMID: 37768032
- DOI: 10.1093/ibd/izad218
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN
Abstract
Background: Whether primary sclerosing cholangitis related to inflammatory bowel disease (PSC-IBD) diagnosed before 6 years (ie, VEO-IBD) has a distinct phenotype and disease course is uninvestigated. We aimed to analyze the characteristics and natural history of VEO-PSC-IBD, compared with early and adolescent-onset PSC-IBD.
Methods: This is a multicenter, retrospective, case-control study from 15 centers affiliated with the Porto and Interest IBD group of ESPGHAN. Demographic, clinical, laboratory, endoscopic, and imaging data were collected at baseline and every 6 months. Inflammatory bowel disease-related (clinical remission, need for systemic steroids and biologics, and surgery) and PSC-related (biliary and portal hypertensive complications, need for treatment escalation and liver transplantation, cholangiocarcinoma, or death) outcomes were compared between the 2 groups.
Results: Sixty-nine children were included, with a median follow-up of 3.63 years (interquartile range, 1-11): 28 with VEO-PSC-IBD (23 UC [82%], 2 IBD-U [7%] and 3 [11%] CD), and 41 with PSC-IBD (37 UC [90%], 3 IBDU [7.5%] and 1 [2.5%] CD). Most patients with UC presented with pancolitis (92% in VEO-PSC-UC vs 85% in PSC-UC, P = .2). A higher number of patients with VEO-PSC-IBD were diagnosed with PSC/autoimmune hepatitis overlap syndrome than older children (24 [92%] vs 27 [67.5%] PSC-IBD, P = .03), whereas no other differences were found for PSC-related variables. Time to biliary strictures and infective cholangitis was lower in the VEO-PSC-IBD group (P = .01 and P = .04, respectively), while no difference was found for other outcomes. No cases of cholangiocarcinoma were reported.
Conclusions: Primary sclerosing cholangitis related to inflammatory bowel disease has similar baseline characteristics whether diagnosed as VEO-IBD or thereafter. A milder disease course in terms of biliary complications characterizes VEO-PSC-IBD.
Keywords: phenotype; primary sclerosing cholangitis; very early onset inflammatory bowel disease; very early onset primary sclerosing cholangitis.
Plain language summary
Very early onset primary sclerosing cholangitis associated with IBD (VEO-PSC-IBD) often presents with autoimmune features and shows a milder PSC disease course than later-onset disease. These findings highlight the significance of studying the distinctive genetic and pathophysiological factors specific to VEO disease.
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.Inflamm Bowel Dis. 2012 Dec;18(12):2270-6. doi: 10.1002/ibd.22938. Epub 2012 Mar 8. Inflamm Bowel Dis. 2012. PMID: 22407885
-
Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.Liver Int. 2018 Mar;38(3):532-541. doi: 10.1111/liv.13548. Epub 2017 Sep 5. Liver Int. 2018. PMID: 28796371
-
Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland.Scand J Gastroenterol. 2019 Aug;54(8):984-990. doi: 10.1080/00365521.2019.1648547. Epub 2019 Aug 10. Scand J Gastroenterol. 2019. PMID: 31402720
-
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World J Gastroenterol. 2015 Feb 14;21(6):1956-71. doi: 10.3748/wjg.v21.i6.1956. World J Gastroenterol. 2015. PMID: 25684965 Free PMC article. Review.
-
Prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis: A systematic review and meta-analysis.Liver Int. 2022 Aug;42(8):1814-1822. doi: 10.1111/liv.15339. Epub 2022 Jun 20. Liver Int. 2022. PMID: 35689520
Cited by
-
Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.Saudi J Gastroenterol. 2025 May 1;31(3):107-136. doi: 10.4103/sjg.sjg_171_24. Epub 2024 Aug 30. Saudi J Gastroenterol. 2025. PMID: 39215473 Free PMC article.
-
Good long-term outcomes of primary sclerosing cholangitis in childhood.JHEP Rep. 2024 May 25;6(8):101123. doi: 10.1016/j.jhepr.2024.101123. eCollection 2024 Aug. JHEP Rep. 2024. PMID: 39139456 Free PMC article.
-
Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease.Dig Dis Sci. 2024 May;69(5):1826-1833. doi: 10.1007/s10620-024-08379-9. Epub 2024 Mar 23. Dig Dis Sci. 2024. PMID: 38521850
-
Risk factors for recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients: A meta-analysis.World J Gastrointest Surg. 2025 Jun 27;17(6):103867. doi: 10.4240/wjgs.v17.i6.103867. World J Gastrointest Surg. 2025. PMID: 40584471 Free PMC article.
-
Transition Readiness in Pediatric Chronic Digestive Diseases: A Regional Perspective from North-Eastern Romania.Medicina (Kaunas). 2024 Dec 22;60(12):2104. doi: 10.3390/medicina60122104. Medicina (Kaunas). 2024. PMID: 39768983 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources